News

The accelerated approval is based on findings from Part 1 of the ESSENCE trial and indicates the agent for noncirrhotic MASH with moderate to advanced fibrosis.

The updated recommendations encourage both patients and clinicians to take a more proactive approach to preventing or managing hypertension.

The therapy's, marketed as Papzimeos, approval is supported by data from a pivotal Phase 1/2 clinical trial.

Phase 4 data reveal esketamine outperforms standard antidepressants in reducing insomnia and boosting next-day well-being in patients with TRD.

Stone clearance was similar with ureteroscopy vs shockwave lithotripsy, but the latter was associated with better recovery and patient-reported outcomes.

Recent research has shown long-lasting freedom of documented AF and atrial tachycardia.

Findings highlight an association between psoriasis and risks of all-cause, cardiovascular, infection-related, and suicide mortality.

Meta-analysis finds omalizumab and remibrutinib most effective for chronic urticaria unresponsive to antihistamines; cyclosporine has greater risks.

Real-world review finds Black patients report fewer dupilumab-related adverse events than White patients.

Parent company Response Pharmaceuticals has announced RDX-002’s achievement of its primary endpoint, with more data to come from an ongoing extension.

The 2 organizations released a joint statement on challenging the common view of HF as an inevitability and prioritizing preventive measures.

Discover how precision medicine and advanced biologics are revolutionizing COPD and asthma management, enhancing patient outcomes and quality of life.

Providing nurses and MAs with an educational video on standardized hair loss photo techniques increased the quantity and quality of documented pictures.

In a Chinese cohort, baricitinib achieved high hair regrowth rates in alopecia areata, totalis, universalis, and eyebrow/eyelash loss, with no serious adverse events.

Survey and RESONATE trial data suggest a -0.22-point drop in the Combined Symptom and Medication Score signal meaningful benefit.

A study links the use of nasal corticosteroids to a greater risk of SARS-CoV-2 infection in adults, but not in children.

Over 11,000 bottles have been voluntarily recalled in response to a consumer complaint of a foreign substance inside a tablet, later identified as aluminum.

The global burden of CKD attributable to high BMI has shown a consistent upward trend from 1990 to 2021, with projections further increases by 2050.

This new monoclonal antibody has achieved a statistically significant improvement in time to treatment failure, indicating a potential to revolutionize ITP.

The FDA approved generic versions of Venofer (iron sucrose) injection from Viatris Inc and Amphastar Pharmaceuticals.

This August 2025 News Update spotlights Ugonabo’s career journey, her award and its story, and the growing importance of tailored dermatologic care for diverse skin tones.

This systematic review and meta-analysis found that biologic switching was shown to be safe and effective among patients with psoriasis.

C difficile carriers had greater baseline hazard for hospital-onset infection than non-carriers, with risk not significantly affected by antibiotic exposure.

Despite obesity’s well-known influence on AF recurrence, neither comorbidity has a significant influence on outcomes from early rhythm control therapy.

FDA grants Fast Track to NRX-100, the first preservative-free IV ketamine, for treating suicidal ideation in depression.

After overcoming 2 FDA rejections, PharmaTher secures approval for ketamine (KETARX) in surgical pain.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025 meeting.